BioSpace News Archive

Sunshine Biopharma Inc. today announced that it has filed a patent application for a potential new treatment for neurodegenerative disorders.

Viracta Therapeutics, Inc. today announced the initiation of a multinational Phase 1b /2 trial in patients with EBV + solid tumors.

Cyclo Therapeutics, Inc. today announced it will participate in the 2021 Virtual Cyclodextrin Conference hosted by CycloLab, “Cyclodextrins as active ingredients in the 21st century,” taking place on October 11, 2021.

Biocept, Inc will present a company overview at the LD Micro Main Event on Wednesday, October 13, 2021 at 11:00 a.m. Pacific time (2:00 p.m. Eastern time).

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of RxDataScience, a leading healthcare-focused data analytics, data management and artificial intelligence (AI) company.

Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the treatment of patients with Urea Cycle Disorders (UCDs).

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, presented the 6-month bone mineral density (BMD) data from its completed Phase 2 clinical trial of EB613, an oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis.

LexaGene Holdings, Inc. today announced Dr. Jack Regan, CEO and Founder, will present live at VirtualInvestorConferences.com on October 7th.

Veracyte, Inc. (Nasdaq: VCYT) announced that four abstracts highlighting the clinical impact of the company’s genomic diagnostic tests for lung cancer and interstitial lung disease (ILD) will be presented at the American College of Chest Physicians (CHEST) Annual Meeting 2021, being held virtually October 17-20, 2021.

NEOGEN Corporation announced that its AquaPrime® NeoKlor and BioSentry® AquaPrime Activator have been reviewed by the Organic Materials Review Institute, and the institute has determined that NEOGEN’s complete chlorine dioxide water treatment system is in compliance with the Canadian Organic Regime regulations, with usage restrictions.